Methods and compositions for treating and preventing inflammatory conditions

Details for Australian Patent Application No. 2004224284 (hide)

Owner Mercia Pharma LLC

Inventors Drivas, Dimitrios T.; Blackburn, Peter

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2004224284

PCT Pub. Number WO2004/084837

Priority 60/457,137 24.03.03 US

Filing date 24 March 2004

Wipo publication date 7 October 2004

International Classifications

A61K 048/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases

Event Publications

3 November 2005 PCT application entered the National Phase

  PCT publication WO2004/084837 Priority application(s): WO2004/084837

1 December 2005 Assignment before Grant

  Mercia Pharma, LLC The application has been assigned to Mercia Pharma, Inc

24 June 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004224289-Production of 5-methyl-N-aryl-2-pyrrolidone and 5methyl-N-cycloalkyl-2-pyrrolidone by reductive amination of levulinic acid with aryl amines

2004224277-Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor